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Abstract
Here, we demonstrated the differentiation potential of murine muscle-derived stem/progenitor cells (MDSPCs) toward
myogenic, neuronal, and glial lineages. MDSPCs, following transplantation into a critical-sized sciatic nerve defect in mice,
showed full regeneration with complete functional recovery of the injured peripheral nerve at 6 weeks post-implantation.
However, several weeks after regeneration of the sciatic nerve, neoplastic growths were observed. The resulting tumors
were malignant peripheral nerve sheath tumors (MPNSTs) with rhabdomyoblastic differentiation, expressing myogenic,
neurogenic, and glial markers, common markers of human malignant triton tumors (MTTs). No signs of tumorigenesis were
observed 17 weeks post-implantation of MDSPCs into the gastrocnemius muscles of dystrophic/mdx mice, or 1 year
following subcutaneous or intravenous injection. While MDSPCs were not oncogenic in nature, the neoplasias were
composed almost entirely of donor cells. Furthermore, cells isolated from the tumors were serially transplantable,
generating tumors when reimplanted into mice. However, this transformation could be abrogated by differentiation of the
cells toward the neurogenic lineage prior to implantation. These results establish that MDSPCs participated in the
regeneration of the injured peripheral nerve but transformed in a microenvironment- and time-dependent manner, when
they likely received concomitant neurogenic and myogenic differentiation signals. This microenvironment-specific
transformation provides a useful mouse model for human MTTs and potentially some insight into the origins of this disease.
Citation: Lavasani M, Pollett JB, Usas A, Thompson SD, Pollett AF, et al. (2013) The Microenvironment-Specific Transformation of Adult Stem Cells Models
Malignant Triton Tumors. PLoS ONE 8(12): e82173. doi:10.1371/journal.pone.0082173
Editor: Atsushi Asakura, University of Minnesota Medical School, United States of America
Received February 13, 2013; Accepted October 31, 2013; Published December 9, 2013
Copyright:  2013 Lavasani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from the Henry J. Mankin Endowed Chair for Orthopaedic Research at the University of Pittsburgh, the William F.
and Jean W. Donaldson Chair at Children’s Hospital of Pittsburgh, the Hirtzel Foundation, and grants from the NIH (R01AR049684, and R01AR047973) and the
Department of Defense (W81XWH04-0003). Cytogenetic analyses were carried out in the UPCI Cytogenetics Facility, supported in part by NIH grant P30CA47904
to Drs. Susanne M. Gollin and Ronald B. Herberman. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: Johnny Huard is a PLOS ONE Editorial Board member and this does not alter the authors’ adherence to all the PLOS ONE policies on
sharing data and materials.
* E-mail: jhuard@pitt.edu (JH); mil39@pitt.edu (ML)
. These authors contributed equally to this work.
Introduction
Stem cells are engaged in constant cross-talk and are influenced
by the signals that they receive from their environment [1]. Cell-
to-cell interaction, cell-to-tissue matrix contact, and the presence
of certain factors and signaling molecules within the stem cell
microenvironment regulate stem cell homeostasis and determine
stem cell fate [1–3]. Hence, it is believed that key fate-determining
events are generated by interactions between the stem cells and
their local environment and are regulated in vivo by environmen-
tal factors encountered in the stem cell niche [4]. It has been
suggested that the environment is a more significant factor in
neural stem cell fate than the intrinsic properties of the cell [5].
Skeletal muscle has shown to contain progenitor cells that can
undergo neuronal or glial lineage differentiation in vitro [6–9] and
in vivo [10], [11]. Muscle-derived stem/progenitor cells
(MDSPCs), isolated using a preplate technique in our lab, have
been shown to regenerate dystrophin-positive myofibers and
myocytes in a dystrophin-deficient mdx mouse model, participate
in bone and cartilage repair after injury, and replenish the bone
marrow of lethally-irradiated mice with no deleterious effects [12–
17]. Although the true origin of MDSPCs is still unclear, recent
studies suggest that they may take their origin from blood vessel
walls, similar to pericytes and endothelial cells [18], [19].
Here we examine the expression of neuronal and glial cell
markers by MDSPCs isolated from murine skeletal muscle under
controlled culture conditions and investigate their regenerative
potential after peripheral nerve injury. In addition to their ability
to undergo myogenesis, MDSPCs are able to generate neuro-
spheres and further differentiate into neuronal and glial lineages,
including Schwann cells. Mice transplanted with MDSPCs
immediately following a critical-sciatic nerve defect exhibited
complete functional recovery, however, several weeks after
regenerating the sciatic nerve, large neoplastic growths were
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observed. The resulting tumors were classified as malignant triton
tumors (MTTs) [20–22] expressing myogenic, neurogenic, and
glial markers.
Previously, we have reported that specific postnatal stem cells
isolated from the skeletal muscle of mice, were also able to undergo
malignant transformation when exposed to conflicting differenti-
ation signals [23]. Furthermore, we found that transformation
appears to be dependent on altering the balance of intrinsic and
extrinsic signaling pathways and can be abrogated when the ability
of a cell to undergo differentiation is removed [23]; hence, it
appears that the transformation of our stem cells was differenti-
ation-dependent. On the basis of our observations in this study, we
hypothesize that MDSPCs were transformed when their intrinsic
and extrinsic signaling pathways became conflicted due to multiple
differentiation signals received at the wound site and that
differentiating the cells prior to implantation stopped transforma-
tion. Herein, we provide a novel animal model of differentiation-
dependent transformation that mimics human MTTs. We believe
that this differentiation-induced transformation model is useful for
studying the initiating events leading to these tumors and will lead
to a better understanding of the mechanisms underlying the
environmental signals and their link to stem cell transformation.
Materials and Methods
Ethics Statement
All animal experiments were performed with the approval of the
University of Pittsburgh Institutional Animal Care and Use
Committee (Animal Welfare Assurance Number A3187-01) under
approved protocol #13-03.
Cell Isolation
A modified preplate technique was used to isolate MDSPCs
from skeletal muscle biopsies obtained from normal C57BL/10J
mice as previously described [13], [24], [25]. MDSPCs were
cultured in proliferation medium containing DMEM supplement-
ed with 10% fetal bovine serum (FBS), 10% horse serum (HS), 1%
penicillin/streptomycin (all from Invitrogen), and 0.5% chick
embryo extract (CEE; Accurate Chemical). The MDSPCs were
then transduced with a retroviral vector encoding a LacZ reporter
gene containing a nuclear localization sequence (nLacZ) to enable
donor cell tracking [26].
Flow Cytometry
Flow cytometry (FACSAria cytometer using FACSDiva soft-
ware; Becton Dickinson) was used to analyze the expression of
CD34, stem cell antigen-1 (Sca-1), and CD45. Cultured MDSPCs
were washed with phosphate buffer saline (PBS; Sigma-Aldrich)
containing 0.5% bovine serum albumin (BSA; Sigma-Aldrich) and
0.1% sodium azide (Sigma-Aldrich). The cells were pelleted,
resuspended in a 1:10 dilution of mouse serum (Sigma-Aldrich) in
PBS that was supplemented with 1 mL of Fc block (rat anti-mouse
CD16/CD32), and incubated for 10 min. Cells were labeled with
biotinylated rat anti-CD34, FITC-conjugated anti-CD45, and a
PE-conjugated rat anti-Sca-1 monoclonal antibody for 30 min. A
separate fraction of cells was treated with equivalent amounts of
isotype control antibodies. All fractions, including the controls,
were washed and labeled with streptavidin-APC for CD34 labeling
for 20 min. Just before analysis, 7-amino-actinomycin D (7-AAD)
was added to each tube to exclude nonviable cells from the
analysis. All antibodies, as well as streptavidin-APC and 7-AAD,
were purchased from BD Biosciences. Live cell events were
collected and analyzed using flow cytometry with a cell sorter
(FACStar Plus or FACSAria; Becton Dickinson).
Myogenic Differentiation
To induce myogenic differentiation, MDSPCs were plated on
collagen type I-coated (Sigma-Aldrich) 24-well plates in prolifer-
ation medium at a density of 1000 cells/cm2 and then shifted to
differentiation medium (DMEM supplemented with 2% FBS and
1% penicillin-streptomycin) 3 days after seeding. In vitro myogenic
differentiation was evaluated after 5 days by immunocytochemical
staining for fast myosin heavy chain (f-MyHC), a marker of late
myogenic differentiation, using the protocol described below.
Neurosphere formation and differentiation
To form neurospheres, MDSPCs were plated as a suspension on
non-treated 12-well plates at a concentration of 46104 cells/mL in
a medium consisting of NeurobasalTM A (Invitrogen), 100 U/mL
penicillin/streptomycin, L-glutamine (2 mM; Invitrogen), supple-
mented with 1X B27 (Invitrogen), basic fibroblast growth factor
(bFGF, 40 ng/mL; Invitrogen), and epidermal growth factor
(EGF, 20 ng/mL; Sigma-Aldrich) using a similar protocol to that
used by Romero-Ramos et al. [6]. Cells were maintained in this
medium for 7 to 14 days, and the growth factors replaced every 3
to 4 days. The MDSPC-derived neurospheres were passaged
before their diameters exceeded 100 mm, by enzymatic (using
TrypLE [GibcoTM]) and mechanical (with P200 plastic micro-
pipettor) dissociation, then were reseeded in NeurobasalTM A
supplemented with B27, bFGF (20 ng/mL), and EGF (10 ng/
mL). To induce differentiation, the MDSPC-derived neurospheres
were collected, centrifuged, and gently triturated in a "differen-
tiation medium" containing NeurobasalTM A supplemented with
10% FBS (Invitrogen) and 1X B27 (Invitrogen). Single cell
suspensions were plated on poly-D-lysine (Sigma-Aldrich, MW
70,000-150,000) coated 8-well CultureSlides (BD FalconTM) at an
initial density of 56104 cells/0.7 cm2. Plates were checked daily to
determine their state of differentiation, and 50% of the medium
was replaced with fresh differentiation medium when necessary
(when the medium became yellow from turning acidic). Cells were
incubated at 37uC in 5% CO2 in a fully humidified atmosphere for
7 to 14 days.
Immunocytochemistry
The MDSPCs, MDSPC-derived neurospheres, and tumor-
derived cells (TDCs) were screened for several lineage-specific
markers. Briefly, cells were fixed for 30 min in 4% paraformal-
dehyde (Fisher Scientific) in PBS (pH 7.4; Invitrogen), washed,
and incubated for 10 min at room temperature with PBS plus
0.3% Triton X-100 to permeabilize the cell membrane. They were
blocked with 10% normal donkey serum (DS; Jackson ImmunoR-
esearch Laboratories) or goat serum (GS; Vector) for 60 min. Cells
were incubated at 4uC overnight with the following primary
antibodies (in 2.5% DS or GS): nestin (1:1000, goat; Santa Cruz
Biotechnology Inc.), neuronal nuclei (Neu-N, 1:100, mouse;
Chemicon), b-tubulin III (TU-20, 1:500, mouse; Chemicon),
neurofilament (NF, 150 kD, 1:500, rabbit; Chemicon), S100
(1:500, rabbit; Sigma-Aldrich), 2’,3’-cyclic-nucleotide 3’-phospho-
diesterase (CNPase, 1:200, mouse; Sigma-Aldrich), glial fibrillary
acidic protein (GFAP, 1:500, rabbit; Chemicon), oligodendrocyte
specific protein (OSP, 1:200, rabbit; Abcam), myelin basic protein
(MBP, 1:500, mouse; Chemicon), Oligodendrocyte marker O4
(1:200, mouse; Chemicon), NG2 Chondroitin Sulfate Proteogly-
can (1:200, rabbit; Chemicon), NGFR p75 (c-20, 1:200, goat;
Santa Cruz Biotechnology Inc.), or TrKA (763, 1:500, rabbit;
Santa Cruz Biotechnology Inc.) The cells were then exposed to the
appropriate secondary antibodies, donkey anti-mouse or rabbit
IgG-AlexaFluorH 594- or 488- conjugated (1:500; Molecular
Probes) for 30 min, and rabbit anti-goat IgG, Cy3-conjugated
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(1:1000; Sigma-Aldrich) for 60 min. For desmin and f-MyHC
immunocytochemical staining, the cells were fixed and blocked
with 10% HS (Vector) and incubated with the primary antibody
(both at 1:200, mouse; Sigma-Aldrich) in 2.5% HS at 4uC
overnight. After gentle washing, the cultures were incubated at
room temperature for 45 min with the secondary antibody,
biotinylated anti-mouse IgG (1:250; Vector), and subsequently
incubated with streptavidin-conjugated Cy3 (1:500; Sigma-Al-
drich) at room temperature for 20 min. To visualize the nuclei, all
cultures were incubated with 49, 69 diamidino-2-phyenylindole
(DAPI, 100 ng/mL; Sigma-Aldrich) for 10 minutes. Culture slides
(BD FalconTM) were mounted with VectashieldH medium
(Vector). Brightfield, phase contrast, and fluorescent images were
taken using a Leica DMIRB microscope equipped with a Retiga
1300 digital camera (Q imaging) and Northern Eclipse software
system (v. 6.0; Empix Imaging, Inc.). Cells were systematically
quantified in at least 15 fields across the slides or culture dish wells
from four to six independent experiments. Controls included
omitting the primary antibodies during the procedure.
Cell Transplantation
To examine myogenic differentiation in vivo, a viable single cell
suspension of 26105 MDSPCs or MDSPC-derived neurospheres
(14 days in culture) were suspended in 20 mL of PBS and injected
into the gastrocnemius muscle of 6- to 8-week-old mdx mice
(C57BL/10ScSn DMDmdx/J; Jackson Laboratories) via an Ultra-
Fine II syringe (BD BioSciences). At 2 and 17 weeks post-
transplantation, mice were sacrificed and the gastrocnemius
muscles were harvested and flash frozen in liquid nitrogen-cooled
2-methybutane. Serial cryosections, 10 mm in thickness, were
prepared from frozen muscles for immunohistochemical analysis.
Muscle regeneration was quantified by manually counting the
number of dystrophin-positive myofibers in a section containing
the largest graft and calculating the regeneration index.
Neurogenic differentiation in vivo was examined by creating a
7 mm sciatic nerve defect in 6- to 8-week-old severe combined
immune deficiency (SCID) mice. Immediately thereafter, a viable
single cell suspension of 36105 MDSPCs, MDSPC-derived
neurospheres, or an equal volume of PBS (15 mL), was injected
onto the proximal and distal nerve stumps. Mice from each group
were sacrificed as early as 6 weeks after transplantation or
maintained for later time points (up to 15 weeks) to check for
possible tumor formation. The hind limbs, including the sciatic
nerve, were harvested, frozen, and cryosectioned for further
analysis.
Soft Agar Analysis
Cells were suspended in DMEM over a 0.6% agar (Sigma)
underlay at concentrations of 100, 500, and 1000 cells/well on a
12 well plate in triplicate. The cultures were allowed to grow for 2
weeks and then colonies were scored as a % (number of colonies/
100 cells).
Cell Cycle Analysis
Cells were trypsinized and washed in PBS prior to fixation in
ethanol (final concentration –70%) for 15 minutes on ice.
Following fixation, the cells were pelleted and resuspended in a
solution containing 50 mg/mL Propidium iodide (PI), 0.1 mg/mL
RNase A and 0.05% Triton X-100. The cells were incubated for
40 min at 37uC and then centrifuged and resuspended in 500mL
PBS and analyzed by flow cytometry.
Cytogenetic Analysis
Cytogenetic analysis was carried out by the University of
Pittsburgh Cancer Institute Cytogenetics Facility. The cells from
both the MDSPC (passage 36) and TDC (passage 12) populations
were harvested following mitotic arrest with a 2 h treatment with
ColcemidTM (0.1 mg/ml, Irvine Scientific). The cells were then
incubated in hypotonic KCl (0.075M) for 30 min at 37uC and
fixed in 3:1 methanol: glacial acetic acid for 20 minutes, followed
by two washes in fixative. Slides were prepared from the cell
suspensions and incubated overnight at 60uC. Chromosomes were
trypsin-Giemsa banded and 20 cells were counted and analyzed
from each cell culture.
Real-Time PCR
To quantify the NF1 gene, we used real-time PCR to determine
the threshold cycle (Ct) number and normalized to Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) as an endogenous
DNA control. Nf1 mRNA was detected by RT-PCR using forward
primer 59-GTATTGAATTGAAGCACCTTTGTTTGG-39 and
reverse primer 59-CTGCCCAAGGCTCCCCCAG-39, 35 cycles
at the melting temperature of 60uC. While GAPDH levels were
determined using forward primer 59- GTCGTGGAGTC-
TACTGGTGTC -39 and reverse primer 59- GAGCCCTTCCA-
CAATGCCAAA -39, 35 cycles at the melting temperature of
60uC. All PCR reactions were performed on a LightCycler 480 II
(Roche Applied Science, Basel, Switzerland). Experiments were
performed with triplicates for each data point. Total RNA was
isolated from our cells using Qiagen’s RNeasy Mini Kit as per
manufacturer’s instructions. For real-time PCR, 1 mg of total RNA
was reverse transcribed to cDNA using Superscript III following
the manufacturer’s protocol (Invitrogen). Real-time qPCR was
performed on 2 ng of cDNA using SYBR Green (Roche) and a
Light Cycler 480II (Roche) in accordance with the manufacturer’s
instructions. All values were normalized to GAPDH expression.
DNA sequencing
Exons 4 to 9 of the Trp53 gene were amplified by PCR. The
PCR products were run out on 1.5% agarose gels. Amplifications
were directly cut from the gel and extracted using Qiagen Gel
Extraction kit as per manufacture’s protocol. Gel-purified PCR
products were sequenced using the BigDye Terminator Cycle
Sequencing Ready Reaction version 1.1 (Applied Biosystems,
Foster City, CA) and run on an ABI Prism 3730 sequencer (Perkin
Elmer, Wellesley, MA). Data were analyzed using Sequencher
software version 4.1.4 (Gene Codes, Ann Arbor, MI) by
comparison to a reference sequence (GenBank, NM_000546).
Primer sequences and PCR amplification conditions are available
on request.
Histochemistry
Sections were fixed in 1% glutaraldehyde (Sigma-Aldrich), and
stained for nLacZ expression (using X-Gal solution 3 hours at
37uC) for donor cell tracking and then counterstained with eosin
[27]. Masson’s trichrome staining was performed per the
manufacturer’s protocol (Masson’s trichrome stain kit, K7228;
IMEB Inc.) to determine the amount of collagen content in the
fibrotic tissue. Muscle fibers are stained red, collagen is stained
blue, and nuclei are black.
Immunohistochemistry
Cryosections were immunostained for FluoroMyelin (Molecular
Probes) according to the protocol provided by the manufacturer,
and then fixed in 4% PFA, blocked with 5% DS for 1 h, and
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incubated with a primary antibody against NF (1:300, rabbit;
Chemicon), for 2 h at room temperature. We then labeled the
cryosections with anti-rabbit secondary antibody conjugated with
AlexaFluorH 594- or 488 for 20 min.
To colocalize donor cells with the glial cell marker CNPase,
tissues were fixed with 4% formalin and blocked with horse serum
for 1 h at room temperature. Sections were then incubated
overnight at 4uC with anti-b-galactosidase (1:200, mouse; Abcam)
primary antibody. The next day, the sections were incubated with
biotinylated horse anti-mouse IgG (1:250; Vector) for 1 h, followed
by a 20 min incubation with Streptavidin-conjugated Cy3 (1:500;
Molecular Probes) to detect the b-galactosidase. Tissues were
blocked again with horse serum for 30 min, incubated with anti-
CNPase (1:200, mouse; Sigma-Aldrich) primary antibody for 2 h
at room temperature, and then with biotinylated horse anti-mouse
IgG (1:250; Vector) for 1 h, followed by a 20 min incubation with
Streptavidin-conjugated FITC (1:500; Molecular Probes) for
CNPase detection. All sections were stained with DAPI (100 ng/
mL; Sigma-Aldrich) for 10 min at room temperature to identify
cell nuclei. For negative controls, the primary antibody was
omitted.
To colocalize donor cells with glial cell marker, GFAP, tissues
were fixed with 4% formalin and blocked with horse serum for 1 h
at room temperature. Sections were then incubated overnight at
4uC with anti-b-galactosidase (1:200, mouse; Abcam) and anti-
GFAP (1:500, rabbit; Chemicon) primary antibodies, followed by
biotinylated horse anti-mouse IgG (1:250; Vector) for 1 h, and a 20
min incubation with Streptavidin-conjugated Cy3 (1:500; Molec-
ular Probes) to detect the b-galactosidase. An incubation of 20 min
with AlexaFluorH 488-conjugated anti-rabbit (1:500; Molecular
Probes) secondary antibody was used to detect GFAP immuno-
reactivity.
To colocalize donor cells with Sca-1, sections were fixed with
4% PFA for 7 min and stained using M.O.M. kit. Briefly, tissues
were blocked with M.O.M.TM Mouse Ig Blocking Reagent for 1
hr at room temperature. To block non-specific binding, Avidin/
Biotin block kit (Vector) was used following the manufacturer’s
instructions. After 5 minutes incubation with M.O.M.TM diluent,
sections were incubated with b-galactosidase (1:200, mouse;
Abcam) and Sca-1 (1:200, rat; BD) for 90 min at room
temperature. The sections were then rinsed in PBS and incubated
with biotinylated horse anti-mouse IgG (1:200; Vector) in diluent
for 15 min. This was followed by a 20 min incubation with
streptavidin-conjugated 594 (1:500; Sigma-Aldrich) for b-galacto-
sidase. The sections were then rinsed and incubated with
biotinylated goat anti-rat IgG (1:250; Vector) in diluent for 20
min and followed by a 20 min incubation with streptavidin-
conjugated 488 (1:500; Sigma-Aldrich) for Sca-1. DAPI was used
to identify cell nuclei. For negative controls, the primary antibody
was omitted.
Tumor sections were stained with VectastainH Elite ABC kit
(Vector Laboratories) following the manufacturer’s protocol with
anti-mouse or -rabbit IgG appropriate to primary antibodies
against NF (1:500, rabbit; Chemicon), S100 (1:500, rabbit; Sigma-
Aldrich), and desmin (1:200, mouse; Sigma-Aldrich). Slides were
then developed using the peroxidase 3, 39-diaminobenzidine
(DAB) substrate kit (Vector Laboratories). For the purpose of
double labeling, a sequential staining of each primary antibody
was performed using anti-rabbit IgG Vectastain ABC kit (Vector
Laboratories). The slides were developed using DAB Substrate Kit
(brown) for NF and VIP Substrate Kit (purple) for S100 (both from
Vector Laboratories).
For dystrophin staining, the gastrocnemius muscles injected
with MDSPCs or TDCs were harvested 14 days after transplan-
tation, flash frozen in liquid-nitrogen-cooled 2-methylbutane, and
serially cryosectioned (10 mm). Sections were fixed with 5%
Formalin for 5 min, rinsed with PBS, blocked with 10% DS for
60 min, and then incubated with anti-dystrophin (1:300, rabbit;
Abcam) primary antibody in 2.5% DS for 60 min. Next, the
sections were washed, then incubated with secondary antibody,
AlexaFluorH 594-conjugated anti-rabbit (1:500; Molecular
Probes), for 20 min. To visualize the nuclei, sections were
incubated with DAPI for 10 minutes. A Nikon Eclipse E800
microscope, equipped with a Spot digital camera and software
system (v. 3.0.4; Diagnostic Instruments), was used for capturing
images to quantify the regenerative index (the number of
dystrophin-positive fibers in the host muscle per 105 transplanted
donor cells).
Functional Assessment
Functional recovery of the sciatic nerve in mice was evaluated
by measuring walking tracks, using a 6646 cm corridor (straight
maze) lined with white paper (Benchkote; Cardinal) and open at
one end to a darkened compartment. The hind paws of the
animals were pressed into the surface of a black waterproof
inkpad. The animals were then walked multiple times to obtain
measurable footprints over a 14 week time period. The animals’
feet were immediately washed in lukewarm water at the end of the
tests. We scanned the collected paw prints with a Microtek
9800XL scanner and evaluated the tracks for toe spread and print
length using the Northern Eclipse software system. We derived
factors for each parameter to calculate the sciatic functional index
using a protocol previously described and validated by Inserra et al.
for mice [28].
Statistical Analysis
The Student’s t-test or the Mann-Whitney Rank Sum test
(where appropriate) were used for direct comparisons between
treatment and control groups using SigmaStat (Jandel Scientific
v2.0). A P value of ,0.05 was regarded as significant.
Results
MDSPC isolation and myogenic differentiation
Muscle-derived stem/progenitor cells (MDSPCs) were isolated
from skeletal muscles of female newborn C57BL/10J mice using a
modified preplate technique [13], [24], [25]. Similar to previously
reported isolates [13], most of these cells were positive for the stem
cell surface markers CD34 (88.5%) and Sca-1 (87%), showing 78%
CD34/Sca-1 double-positive cells by flow cytometry. Very few
cells expressed the myogenic cell marker desmin (,1.5%)
following immunofluorescence staining. The cells were initially
plated at a density of 250 cells/cm2 at 20-30% confluency and
transduced with a retroviral vector containing an nLacZ reporter
gene [12], [13], [16] for donor cell tracking. The cells were
subcloned to obtain a population of MDSPCs that was over 90%
b-gal-positive (data not shown). We found no significant difference
in cell marker expression compared to the parental MDSPCs
suggesting the stability of these cells in vitro.
As expected, MDSPCs fused and formed multinucleated
myotubes expressing f-MyHC (Fig. 1A). In order to further
explore the myogenic potential of MDSPCs, their ability to
regenerate dystrophin-positive muscle fibers after intramuscular
implantation in dystrophin-deficient mdx mice was examined
(n=10). Fourteen days post-implantation, many dystrophin-
positive myofibers could be found within the injected muscle
(Fig. 1B). Furthermore, donor nLacZ-positive nuclei could be
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observed within the regenerated myofibers 17 weeks (120 days)
post-implantation (Fig. 1C).
MDSPCs can undergo neuronal and glial differentiation
in vitro
The MDSPCs were screened by immunocytochemistry for a
series of neurogenic and glial cell markers prior to differentiation.
Undifferentiated MDSPCs showed phenotypic heterogeneity by
their expression of cell markers that label neuroepithelial
progenitors (nestin, 9164.9%), oligodendrocytes and Schwann
cells (CNPase, 8869.0%), and postmitotic neurons (NF,
53614.0%); however, they were negative for other cell markers
of neuronal maturity, such as neuronal nuclei, Neu-N. When
MDSPCs were cultured in defined serum-free medium supple-
mented with epidermal growth factor (EGF) and basic fibroblast
growth factor (bFGF) [6], they generated free-floating clusters of
cells (MDSPC-derived neurospheres) within 7 to 10 days (bright-
field; Fig. 1D). Many of the cells on the outer surface displayed
microspikes—a characteristic of neurospheres evident at higher
magnification [6] (data not shown). These MDSPC-derived
neurospheres expressed neuronal markers (b-tubulin III, NF,
and Neu-N), a marker for myelin producing oligodendrocytes and
Schwann cells (CNPase), and the astrocytic marker GFAP (inset;
Fig. 1D). Though these MDSPC-derived neurospheres expressed
neuronal and glial lineage commitment markers, they also retained
expression of the neuroendothelial progenitor marker nestin (inset;
Fig. 1D).
The MDSPCs, unlike some neural stem cells derived from the
developing brain [29], appear to require exogenous factors to
trigger commitment to a neurogenic cell lineage. A negatively
charged culture surface, high serum levels, and eliminating
mitogens, were all required to further induce neuronal and glial
differentiation of the MDSPC-derived neurospheres. After 3 days
in culture, the neurospheres differentiated into a variety of cell
types with diverse morphologies; including small and round, large
and flat, spindle-shaped, and round cell bodies with thin extended
processes (phase contrast; Fig. 1E). Over 70% of cells were positive
for the neuronal markers b-tubulin (n; Fig. 1E) and NF (data not
shown), 88% were positive for the astrocyte marker GFAP (a; Fig.
1E), 22% expressed the immature oligodendrocyte marker NG2
(o; Fig. 1E), and 65% displayed the mature oligodendrocyte
marker O4 (data not shown). The simultaneous expression of both
neuronal and astrocyte cell markers has been observed previously
in vitro in hippocampal stem cells treated with bFGF in serum-free
medium [30], in the rat embryonic striatum at early stages of
differentiation [31], and in immortalized embryonic mesencephal-
ic mouse cells [32]. Similarly, postnatal forebrain neural progen-
itors can display mixed glial and neuronal properties in vitro when
they co-express neuron-specific enolase (NSE), NF, and GFAP
[33]. Thus, co-expression of glial and neuronal cell markers seems
to reflect multipotentiality at early stages of neurogenic differen-
tiation in vitro. MDSPC-derived neurospheres expressed nestin
(Fig. 1F) and could be further differentiated into neuronal, glial,
and Schwann cell lineages positive for NF (Fig. 1G), S100 (Fig.
1H), O4 (Fig. 1I), OSP (Fig. 1J), MBP (Fig. 1K), CNPase (Fig. 1L),
GFAP (Fig. 1M), p75 (Fig. 1N) and TrkA (Fig. 1O). Taken
together these results indicate that MDSPC-derived neurospheres
can differentiate into neurogenic and glial lineages, including
Schwann cells, in vitro.
MDSPCs differentiate into Schwann cells in vivo and
participate in the regeneration of the injured peripheral
nerve
To test the ability of MDSPCs to participate in the regeneration
of the peripheral nerve following injury, the cells were implanted
into a critical-size sciatic nerve defect (a defect unable to undergo
autonomous healing) in mice. The removal of a 4 to 5 mm nerve
segment (Fig. 2A) resulted in a ,6.5 to 7 mm critical-size defect
due to the retraction of the nerve ends (Fig. 2B). The vehicle (PBS)
group exhibited no regeneration (n=24); some nerve sprouting on
the proximal side of the defect and neuroma formation (a bulb-
shaped thickening created by ineffective and unregulated nerve
regeneration) were the main outcomes (data not shown). However,
complete sciatic nerve regeneration was observed by 5 to 9 weeks
in all of the MDSPC implanted mice (n=28; Fig. 2C). Notably,
blood vessel networks were also present around all regenerated
nerves (arrowhead; Fig. 2C). The regenerated nerves contained
many donor nLacZ-positive cells (Fig. 2D) and exhibited both NF-
(green) and CNPase immunoreactivity (red; Fig. 2E). Furthermore,
the regenerated nerve contained short nerve segments with node-
like discontinuities in the myelin sheet (CNPase, red) that
resembled nodes of Ranvier-like structures (white circles; Fig.
2F). Cross sections of regenerated nerves exhibited many
regenerated NF-positive axons (green) encompassed by Fluoro-
Myelin (red), indicating the presence of myelin-producing
Schwann cells that form the myelin sheaths surrounding the
regenerated axons (Fig. 2G). To confirm the differentiation of
donor cells to glial lineage, we were able to detect b-gal positive
cells (red nucleated cells) expressing the glial and Schwann cell
markers GFAP (green; Fig. 2H, 2I) and CNPase (green; Fig. 2J)
along the regenerated sciatic nerve.
Quantitative measurement of morphometric parameters, such
as number of myelinated axons, myelin thickness, myelinated fiber
area, axonal area, and g-ratio (axonal area : myelinated fiber area)
[34] were compared between uninjured control (n=2) and
MDSPC-transplanted nerves (n=3) in images taken with a
transmission electron microscope (TEM; Fig. 2K-M). Ten weeks
after implantation, the mid-section of the regenerated sciatic nerve
(MDSPC-transplanted) contained an average of 576633 myelin-
ated axons compared to 387612 in the uninjured nerves
Figure 1. MDSPCs exhibit myogenic, neurogenic, and glial differentiation. (A) Ten days after culture in low serum differentiation medium,
MDSPCs differentiated into multinucleated myotubes expressing f-MyHC (red) (overlaid on nuclear counterstain [DAPI; blue]). (B) Many regenerated
dystrophin-positive myofibers (red) are observed in gastrocnemius muscle cryosections of mdx mice (n = 10) 14 days after injection. (C) The nLacZ-
positive donor-derived MDSPCs (blue) could be detected in regenerated myofibers 17 weeks after injections. (D) MDSPCs were able to generate
neurospheres (three-dimensional non-adherent clusters of cells) in enriched-culture medium within 7 to 10 days in culture (brightfield image).
MDSPC-derived neurospheres express the neuronal cell markers b-tubulin III, NF, Neu-N, the myelin producing oligodendrocytes marker CNPase, the
astrocytic marker GFAP, and retained their nestin (a neuroepithelial progenitor marker) expression (inset). Antibodies used are visualized in red with
the nuclear stain, DAPI seen in blue. (E) The MDSPC-derived neurospheres can be further differentiated into neurons (b-tubulin [red], n),
oligodendrocytes (NG2 [green], o), and astrocytes (GFAP [green], a) (inset). MDSPC-derived neurospheres expressed (F) nestin and were differentiated
further into cells that expressed markers found on neuronal and glial (including oligodendrocytes, astrocytes, and Schwann cells) cells, including (G)
NF, (H) S100, (I) O4, (J) OSP, (K) MBP, (L) CNPase, (M) GFAP, (N) the neurotrophin receptor p75, and (O) the tyrosine kinase receptor TrkA (all green,
except O4 [red]). The nuclear stain DAPI seen in blue and b-gal-positive nuclei in red (for H and J-O). Data represent four to six independent
experiments. Scale bars represent 100 mm (A-D) or 50 mm (E-O).
doi:10.1371/journal.pone.0082173.g001
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(P,0.001). Myelinated fiber area and myelin thickness were
assessed as a measure of regenerated fiber maturation. Myelinated
axons in the MDSPC-transplanted group showed a median cross-
sectional area of 8.53 mm2, versus 13.8 mm2 for the uninjured
group (P,0.001, graph not shown) and a median myelin thickness
area of 5.07 mm2 as compared to 7.1 mm2 for the uninjured
control group (P,0.001, graph not shown). The median and 25th
to 75th percentiles of g-ratio in mid-sections of the regenerated
nerves were 0.40% and 0.28% to 0.48%, respectively, versus the
uninjured control group which was 0.50% and 0.42% to 0.56%,
respectively, (P,0.001; Fig. 2N). The increase in the number of
myelinated axons following MDSPC transplantation may be the
result of axonal branching leading to an increased target organ
reinnervation and thus less axonal dieback [35]. Although the
regenerated peripheral nerves are significantly different from the
uninjured nerves for all morphometric parameters mentioned, we
Figure 2. Transplanted MDSPCs foster repair of critical-size sciatic nerve defects. (A) A 4- to 5 mm segment of the sciatic nerve was
removed from the hind limb of each mouse, (B) resulting in a 6.5 to 7 mm defect. (C) Following transplantation of MDSPCs into the defect, complete
regeneration from proximal to distal end was observed (n = 28). Blood vessel networks (arrowheads) were also present around all regenerated
nerves. (D) Many nLacZ-positive cells (blue) were observed between weeks 5 and 9 following injury. ‘‘p’’ corresponds to the proximal stump and ‘‘d’’
to the distal stump. (E) The regenerated nerve exhibited both NF (green) and CNPase (red) immunoreactivity. (F) CNPase (red) staining of the
regenerated sciatic nerve revealed nodes of Ranvier-like structures (white circles). (G) Cross-sections of regenerated nerve showed nLacZ-positive
cells (blue) and exhibited NF-positive axons (green, inset) encompassed by FluoroMyelin-positive cells (red, inset). (H, I, J) Colocalization of b-gal (red)
with (H, I) GFAP (green) or (J) CNPase (green), and DAPI (blue) suggests possible differentiation of the MDSPCs into Schwann cells (double-positive
cells denoted by arrows). (K-M) Electron microscopy of semi-thin cross-sections of (K) non-operated (uninjured) control, and (L, M) MDSPC-
regenerated peripheral nerve 10 weeks after implantation, show a high number of myelin-producing Schwann cells. Arrows indicate Schwann cells
surrounding the myelinated axon. ‘‘Sc’’ corresponds to Schwann cells, ‘‘M’’ to myelin sheath, and ‘‘Ax’’ to axons. (N) Graphical quantification of the g-
ratio (axonal area: myelinated fiber area) represents the median values of both uninjured and MDSPC-regenerated nerves (P,0.001, Mann-Whitney
Rank Sum Test). Sciatic nerve regeneration studies represent three independent experiments. The morphometric parameters represent results from 5
mice (2 controls and 3 treated) and analysis of 1000 fibers. Scale bars represent 100 mm (D, E, and G) or 10 mm (F, H-M).
doi:10.1371/journal.pone.0082173.g002
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believe the high number of myelin-producing Schwann cells
(arrows; Fig. 2M) and the low g-ratio (Fig. 2N) indicate thick
myelination of the regenerated axons, highlighting the process of
myelination exhibited in the MDSPC-transplanted group.
Functional recovery of regenerated sciatic nerves was deter-
mined by monitoring mice on a walking track. According to paw
print analysis, MDSPC-treated mice improved their walking
pattern, evidenced by wider toe spread and shorter print length
(Fig. 3A). Further quantifications of paw prints revealed functional
recovery as determined by a decrease in toe spread factor (Fig. 3B),
a decrease in print length factor (Fig. 3C), and an increase in
sciatic functional index (SFI; Fig. 3D), when compared to PBS-
treated control mice. Cell transplantation significantly decreased
the toe spread factor (0.32660.058 versus 0.60462.51 for PBS-
treated mice, P,0.01) and print length factor (0.13260.05 versus
0.2460.036 for PBS-treated mice, P,0.01) at 6 weeks post-
transplantation. These differences became more evident at 10
weeks, (toe spread 0.25960.097 versus 0.55860.026 for PBS-
treated mice, P,0.01 and print length 0.11760.054 versus
0.20960.052 for PBS-treated mice, P,0.01). The first signs of
motor nerve recovery could be observed at 6 weeks post-
transplantation for the MDSPC-transplanted groups (SFI: –
52.465.30) versus PBS-treated mice (SFI: –9062.51, P,0.001).
After 10 weeks, the MDSPC-transplanted groups (–45.2614.2,
P,0.01) demonstrated further improvement in comparison to the
PBS-treated control groups (–86.164.28).
MDSPCs undergo environment-specific transformation
11 weeks post-transplantation into a sciatic nerve defect
Approximately 70% of donor cells (nLacZ-positive) present in
the regenerating sciatic nerve at 5 weeks post-implantation were
Sca1-positive, indicating that a large proportion of donor
MDSPCs remain as progenitor cells weeks after transplantation
(Figure S1). Although complete nerve regeneration was observed 6
weeks post-implantation, 70% of the mice (n=28) formed large
neoplastic growths between weeks 11 and 13 (Fig. 4A, B). As these
neoplasias were composed almost entirely of nLacZ-positive cells
(data not shown), the neoplasias were highly invasive and positive
for the myogenic markers a-smooth muscle actin (Fig. 4C, D) and
desmin (Fig. 4E, F). The tumors were also positive for the
neurogenic marker NF (Fig. 4G, H), contained focal areas positive
for S100 (Fig. 4I, J), areas that are double-positive for both NF
(brown) and S100 (purple; Fig. 4K, L), and pockets of unorganized
myelin deposition, as seen by FluoroMyelin staining (Fig. 4M, N).
According to histological features, the resulting tumors were
classified as malignant peripheral nerve sheath tumors (MPNSTs)
with rhabdomyoblastic differentiation, otherwise known as "Triton
tumors" [20–22]. Notably, while tumorigenesis was observed,
nerve regeneration was still apparent (white arrow indicating
regenerated nerve; Fig. 4O), implying that tissue regeneration and
cellular transformation may not be mutually exclusive events.
Cells isolated from MDSPC-derived tumors grow as
neurosphere-like structures
Tumor-derived cells (TDCs) cultured in proliferation medium,
grew spontaneously as neurosphere-like structures in the absence
of neurogenic stimulation (Fig. 5A) and were nLac-Z positive (Fig.
5B). These neurosphere-like structures were positive for b-tubulin
III (Fig. 5C), CNPase (Fig. 5D), GFAP (Fig. 5E), nestin (Fig. 5F),
and NF (Fig. 5G), but were negative for Neu-N (Fig. 5H).
Furthermore, as determined by soft agar assays, TDCs had gained
the ability to grow independently of anchorage, while their
parental counterparts (MDSPCs) were incapable of forming
colonies (data not shown). Cell cycle analysis of the parental
MDSPCs and TDCs revealed a shift of DNA content of the TDCs
from the majority of cells being in the G0/G1 phase (parental
45.6% vs. TDCs 10.8%) to the G2/M phase (parental 34.6% vs.
TDCs 66.7%), with over 50% of the TDCs possessing more than a
diploid amount of DNA (Fig. 5I-L). We carried out cytogenetic
analysis on both MDSPC (Fig. 5M) and TDC populations (Fig.
5N). Analysis of the MDSPC culture revealed murine chromo-
somes with near-diploid and near-tetraploid chromosome consti-
tutions; no clonal structural abnormalities were observed. How-
ever, analysis of the TDCs revealed chromosome numbers ranging
from 46-118. None of the TDCs had a chromosome complement
that would be considered normal diploid or tetraploid. Two of the
structural abnormalities observed in the TDCs appear to be
clonal, since they were each observed in more than one cell. Both
of these were large, unidentifiable marker chromosomes, one of
which appeared to be dicentric. Nonclonal chromosome abnor-
malities were seen in each of the TDCs. The karyotypic variability
in these cells suggests the presence of chromosomal instability [36].
Genetic Analysis of MDSPC-derived Tumor Cells
To determine the level of Nf1 expression, real-time PCR
analysis was performed on the mouse Nf1 gene to look at relative
expression in cells pre- and post-implantation. The Nf1 gene was
expressed in both pre- and post-transplantation cells. There is a
slight decrease in the Nf1 gene expression post-implantation
(normalized Ct-values of 27.45 vs. 28.8 respectively), however, this
Figure 3. Transplanted MDSPCs assist in functional recovery of
critically-sized sciatic nerve defects. (A) A depiction of represen-
tative paw prints from control- and MDSPC-implanted mice at 6 and 10
weeks post-implantation. (B-D) Quantification of paw print analyses,
indicating that MDSPC transplantation increases the ability of the mice
to walk normally, displayed a (B) decrease in toe spread factor, (C)
decrease in print length factor, and (D) an increase in SFI (sciatic
functional index) compared to PBS-treated mice. Thirty-five paw prints
were analyzed per group for each time point. Error bars indicate s.e.m.
(*P,0.05 and **P,0.001, Mann-Whitney Rank Sum Test).
doi:10.1371/journal.pone.0082173.g003
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trend was not significant (p = 0.068, t-test). To investigate for
mutations in the Trp53 gene, sequencing of exons 4 to 9 was
performed on DNA from cells pre- and post-implantation. The
sequence of the Trp53 gene pre- and post-implantation contained
no discernible transformation mutations.
TDCs generate tumors when implanted in vivo
To determine whether the TDCs were able to regenerate
tumors, the cells were implanted into a critical-sized sciatic nerve
defect in mice (n=16). Following implantation, neoplastic growths
were observed between 4 and 8 weeks in all implanted mice.
Furthermore, these tumors were highly aggressive and invaded all
of the surrounding tissue of the leg, destroying muscle as well as
bone (arrows), and were composed of poorly undifferentiated
rhabdomyoblasts (small blue and pink cells) (Fig. 6A, B).
TDCs maintained their ability to undergo myogenesis in
vitro but formed tumors when implanted into the
skeletal muscle
Though TDCs appear to be spontaneously neurogenic, they
express the myogenic marker desmin (red, 12%; Fig. 6C) and
retain their ability to form f-MyHC-positive myotubes in vitro (Fig.
6D). While the parental MDSPCs regenerated muscle fibers and
showed no sign of tumorigenesis up to 17 weeks post-implantation
(n=10; Fig. 6E), the TDCs rapidly formed tumors when injected
into the skeletal muscle of mice (n=10). These tumors formed 4
weeks post-implantation in 100% of the mice and were composed
Figure 4. Between weeks 11 and 13, approximately 70% of the mice (n = 28) implanted with MDSPCs formed large neoplastic
growths. (A, B) Representative image of hematoxylin and eosin staining of tumors that formed in mice implanted with MDSPCs. (C-L) The resulting
tumors were classified as malignant peripheral nerve sheath tumors with rhabdomyoblastic differentiation (Triton tumors) by showing positivity for
(C, D) smooth muscle actin (brown), (E, F) desmin (brown), (G, H) NF (brown), and pockets of (I, J) S100 (brown), (K, L) as well as cells positive for
both NF (brown) and S100 (purple). Positive cells (brown, C-J) or double-positive cells (K and L) are indicated by black arrows. Images B, D, F, H, J, and
L show a higher magnification image of the image they were preceded by. (M, N) The neoplasias were also positive for FluoroMyelin (green),
showing areas of unorganized myelin deposition. (O) Image depicting NF (green) and FluoroMyelin (red) double-stained sections from a regenerated
nerve (white arrow) in the area of tumorigenesis. Negative control sections were similarly processed without primary antibodies. Scale bars represent
100 mm.
doi:10.1371/journal.pone.0082173.g004
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of donor nLacZ-positive cells (Fig. 6F). A schematic representation
of these results is shown in Figure 6G. Of note, injection of
parental MDSPCs, subcutaneously or intravenously, exhibited no
signs of tumor formation up to 1 year post-implantation (data not
shown).
In vitro differentiation of MDSPCs eliminates niche-
specific transformation
To rule out the possibility that our perceived transformation was
due to the presence of pre-transformed cells within our MDSPC
population, and was, in fact, due to an imbalance of intrinsic and
extrinsic signaling, we altered the intrinsic predilection of the cells
by differentiating them prior to implantation. If environmental
cues were leading to the transformation of MDSPCs, then altering
the ability of cells to differentiate to a committed lineage should
abrogate transformation. Therefore, MDSPCs were cultured as
neurospheres for 14 days, dissociated to a single cell suspension,
and implanted into either the skeletal muscle of dystrophic mice or
a critical-sized sciatic nerve defect. When the dissociated neuro-
spheres were injected into the skeletal muscle of mdx mice, poor
muscle engraftment was observed (Fig. 7A, B), as evident by a
Figure 5. TDCs maintain their neurogenic and myogenic differentiation potential in vitro. (A) TDCs grew as neurosphere-like structures in
the absence of neurogenic medium, and (B) were nLacZ-positive (blue). (C-H) Immunofluorescent analysis of these spontaneously-occurring
neurosphere-like structures demonstrated that they were positive for (C) b-tubulin III, (D) CNPase, (E) GFAP, (F) nestin, and (G) NF, but were negative
for (H) Neu-N. For all immunofluorescence, the antibodies used are visualized in red, with the nuclear stain DAPI seen in blue. (I-L) Cell cycle analysis
of the parental MDSPCs and TDCs was performed by FACS. Shown is the (I, J) DNA content and (K, L) graphical representation of the results,
indicating the apoptotic, G0/G1, S, and G2/M fractions. (M, N) Karyotypic analysis of MDSPCs and TDCs. (M) Depicted is a representative karyotype
from the MDSPC population (40, XX). (N) Karyotype of one of the TDCs that has 68 chromosomes, is hypertriploid, and expresses several
unidentifiable marker chromosomes, the largest of which appears to be dicentric. Scale bars represent 100 mm.
doi:10.1371/journal.pone.0082173.g005
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decrease in regeneration index (number of dystrophin positive
myofibers per 100,000 injected cells) compared to parental
MDSPCs (36.769.45 versus parental MDSPCs 180.2649.1,
P,0.001; Fig. 7C). This suggests that in vitro differentiation of
cells towards a neurogenic lineage reduced the ability of the cells to
undergo myogenic differentiation. This was expected, since we
postulated that differentiation of MDSPCs prior to implantation
would diminish their ability to respond to local environmental
cues. More interestingly, when the dissociated MDSPC-derived
neurospheres were implanted into a critical-sized nerve defect of
mice, no tumor formation was observed (n=5), however, 80% of
the mice formed fibrotic masses positive for collagen by Masson’s
trichrome staining 4 weeks post-implantation (as seen by intense
collagen deposits [blue]; Fig. 7D-E), while the remaining mouse
exhibited no signs of tumor formation, nerve regeneration, or
fibrosis. In comparison, the implanted parental MDSPCs gener-
ated large neoplastic growths that contained almost no Trichrome-
positive areas (5.63%61.6 versus neurosphere-implanted group
32.5%616.1, P,0.001; Fig. 7F). These findings are summarized
in the schematic representation shown in Figure 7G.
Discussion
In the process of investigating the potential of murine postnatal
MDSPCs to regenerate peripheral nerve, we have isolated a
population of stem/progenitor cells that are able to differentiate
into muscle, neuronal, and glial cells depending on the environ-
mental cues that they receive. Although these cells appear to have
tremendous regenerative potential, they form neoplastic growths,
classified as MTTs [22], between 11 and 13 weeks post-
implantation, but only when implanted into a sciatic nerve defect.
MTTs, referred to as MPNSTs with rhabdomyoblastic differen-
tiation [20], are an uncommon malignancy in humans, which are
believed to originate from the neurilemmal sheath of peripheral
nerve fibers [37] or from cells associated with the nerve sheath,
such as Schwann cells, perineural cells, or fibroblasts; they
comprise approximately 5–10% of all soft tissue sarcomas [22],
[38]. MTTs are aggressive cancers with crude two- and five-year
survival rates of 33% and 12%, respectively [39], [40]. For a
tumor to be classified as an MTT, it must meet the following
criteria: (i) originate along a peripheral nerve, or represent a
metastasis from such a tumor, (ii) have growth characteristics of a
Schwann cell tumor phenotype, and, (iii) demonstrate that
rhabdomyoblasts can arise from within the body of the tumor
[21]. Based on the analysis of the tumors generated here and
consultation with independent pathologists, the generated tumors
fit the criteria to be classified as MTTs. Furthermore, MTTs have
been shown to be positive for S100, desmin, muscle-specific actin,
and myogenin; [21], [38] all of which are exhibited by our
observed tumors. Furthermore, based on our cytogenetic analyses
Figure 6. TDCs can regenerate tumors in vivo. (A, B) Hematoxylin and eosin staining of a tumor generated from TDCs implanted into a sciatic
nerve defect in mice (n = 16) demonstrates the destruction of the bone, as seen by the smooth and pink stained portion (arrows). (C, D) In vitro
myogenic analysis demonstrates that the TDCs possess expression of (C) the myogenic marker desmin (red, 12%) and have the ability to form
myotubes in vitro, as seen by (D) f-MyHC staining (red). (E, F) In vivo myogenic analysis demonstrates that although (E) parental MDSPCs (blue)
showed myofiber regeneration (muscles stained with eosin) after injection into the gastrocnemius muscles of mdx mice and were detected up to 17
weeks without sign of tumor formation (n = 10), the (F) TDCs (blue) implanted into the muscle formed tumor 100% of the time (n = 10), and as early
as 4 weeks post-implantation. (G) A schematic of the experimental design and results displayed above. Negative control sections were similarly
processed without primary antibodies. Scale bars represent 250 mm (A) or 100 mm (B-F).
doi:10.1371/journal.pone.0082173.g006
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of primary MTTs, and as seen by others [41], it appears that the
tumor-derived cells are genetically unstable, displaying more than
normal modality. Similarly, the cell cycle analysis shows that the
majority of these cells had increased DNA content, with 67% of
the cells in the G2/M tetraploid state.
It was originally believed that these tumors were caused by
either Schwann cells inducing muscular differentiation of other
cells, or by malignant Schwann cells transforming directly into
striated muscle cells [20]. This latter theory is the more widely
accepted concept as it is possible that Schwann cells, being of
neural crest origin, may retain a capacity for mesenchymal
differentiation [40]. In 1921, Rotter postulated that adult cancers
arise from the inappropriate reactivation of embryonal cell-like
progenitor cells within adult tissues [42]. Herein, we posit an
alternative theory and provide an experimental mouse model
along with the possible explanation for the origins of Triton
tumors. Based on our results, we hypothesize that Triton tumors
may originate from the "inappropriate activation" of progenitor
cells present in skeletal muscle that become transformed when
activated and exposed to a neurogenic stimulus.
Previously, we have shown how a lack of regulation of these
signals is involved in the initiation of the oncogenic potential of
specific populations of MDSPCs [23]. In this model, for the
spontaneous transformation of somatic stem cells, progenitor cells
isolated from the skeletal muscle of mice show spontaneous
microenvironment-specific transformation when expressing the
Figure 7. Differentiation of MDSPCs to a neurogenic lineage prior to implantation decreases their ability to respond to
environmental cues and stops transformation. (A-C) Two weeks post-implantation MDSPC-derived neurospheres showed a reduction in
muscle regeneration when compared to the parental MDSPCs. (A) The nLacZ donor-derived MDSPC-derived neurospheres (blue) could be detected
in eosin stained regenerated myofibers and (B) showed fewer regenerated dystrophin-positive myofibers (red) compared to undifferentiated
MDSPCs. (C) Graphical representation of the regeneration index (number of dystrophin positive fibers/100,000 injected cells) of parental MDSPCs and
MDSPC-derived neurospheres (NS). NS-injected mice yield a lower regeneration index compared to the undifferentiated MDSPCs. Error bars indicate
6 s.d. (**P,0.001, Mann-Whitney Rank Sum Test). (D-F) When dissociated MDSPC-derived neurospheres were implanted into a sciatic nerve defect,
tumor formation was abrogated. Furthermore, 80% of mice (n = 5) formed large fibrotic masses, as seen by (D) eosin staining with nLacZ donor
MDSPC-derived neurospheres shown in blue, in addition to (E) intense collagen deposits identified with Masson’s Trichrome staining (blue). (F)
Graphical representation of the Trichrome-positive area of parental MDSPCs and NS. Parental MDSPCs show minimal signs of fibrosis evident by a
lower percentage of collagen-positive area. Error bars indicate6 s.d. (**P,0.001, Mann-Whitney Rank Sum Test). (G) A schematic of the experimental
design and results. Scale bars represent 10 mm.
doi:10.1371/journal.pone.0082173.g007
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osteogenic factor BMP4 [23]. The tumors generated were
osteorhabdomyosarcomas and formed only when a specific
population of MDSPCs was transduced with BMP4 and implanted
into a myogenic environment [23]. The finding that stem cells can
undergo spontaneous transformation is not unique to MDSPCs.
Embryonic stem cells (ES) and testicular stem cells (TS) have been
shown to form teratomas when implanted outside of their native
environments [43–49]. Co-culturing human ESCs with immor-
talized human astrocytes from fetal midbrain tissue cells (making
them more similar to adult progenitor cells prior to implantation)
resulted in substantial and long-lasting restitution of motor
function when transplanted into a Parkinsonian mouse model
[50]. Interestingly, the component of the regenerated tissue that
was comprised of slowly-dividing cells was potentially tumorigenic.
These cells resembled a population of neuroepithelial cells that
had failed to differentiate [50]. Mesenchymal stem cells (MSCs)
have been shown to become tumorigenic [51–53] and have been
implicated in childhood leukemia [54], epithelial cancers [55], and
osteosarcomas [56–58]. It has also been shown that leukemic stem
cells express antigens similar to those expressed by hematopoietic
stem cells (HSCs) [59]. Furthermore, the concept of peripheral
nerve regeneration inducing tumors is not new. Though periph-
eral nerves have the capacity to repair and restore their function,
complete recovery after peripheral nerve lesion rarely occurs in the
clinical setting [60], [61]. Often, as a result of improper and
irregularly regenerating nerve fibers, benign (non-malignant)
tumors (neuromas) develop [61].
In light of these findings, we posit that there are two distinct
populations within our pool of cells2 one that is actively cycling
and the other that is slower to cycle (quiescent), remaining as a
‘‘reserve’’ pool. When these cells are implanted in a mouse sciatic
nerve defect, the cycling cells undergo glial differentiation and
assist in the regeneration of the peripheral nerve, while the reserve
cells remain quiescent. As the cycling cells become depleted to
differentiation, the quiescent cells become ‘‘activated’’. However,
when the healing is complete, the neurogenic/glial signals
generated from the injury decrease and the newly activated
reserve cells begin to respond to both the decreased neurogenic/
glial signals from the injury, as well as the myogenic environmental
cues (which are no longer masked by the neurogenic/glial signals).
Since the reserve cells have the capacity to respond to both the
environmental myogenic signals as well as the signals generated
from the injury, these two signals disrupt cellular homeostasis and,
in time, lead to transformation. This may explains why our model
initially displays peripheral nerve regeneration, followed by
transformation weeks later. This is supported by our observation
that clusters of Sca1-positive progenitor donor cells are still present
in the regenerating nerve before the transformation was initiated.
The previously introduced idea of a close association between
wound healing and tumorigenesis by Rudolf Virchow in 1863, has
been further evaluated in the past decade [62] and highlights the
recent observation that adult myelinating Schwann cells in
neurofibromatosis type 1 (NF1)-deficient mice develop normal
nerve. However, only after a sciatic nerve injury did loss of Nf1
expression induce tumorigenesis, providing evidence that micro-
environment signals at the wound site can be tumor-promoting
[63]. The direct mechanism of transformation and the environ-
mental signals involved with our observed tumorigenesis have yet
to be elucidated, it is most likely that key molecules found in both
myogenesis and neurogenesis are potential candidates. Loss of Nf1
expression and mutations in the p53 tumor suppressor gene has
been reported in many of the human and animal models of
MPNSTs. However, we found no significant alteration in Nf1 gene
expression or any transformation mutations in the Trp53 gene in
our cells pre- and post-transplantation. Our results are in
agreement with molecular analysis performed in a study by
Strauss et al. [64], reporting the retention of Nf1 gene expression
in sporadically occurring human Triton tumors, suggesting that
loss of Nf1 expression is not required for the development of
MPNSTs. Also, key observations in a mouse model of NF1 show
that tumors only developed in a heterozygous (Nf1+/2) back-
ground, implicating other Nf1+/2 cell types in neurofibroma
formation and Nf1 loss of heterozygosity (LOH) in the Schwann
cell lineage is necessary, but not sufficient, to elicit neurofibromas
[65], [66]. Interestingly, our findings are also in accordance with
an extensive study by Verdijk’s group that included a compre-
hensive review of literature, plus 145 MPNST cases over 36 years,
assessing the Trp53 gene mutation frequency. The results of their
study indicate that in contrast to current animal models of
MPNSTs, Trp53 mutations are relatively rare in human MPNSTs.
They also found no correlation between p53 immunostaining or
TP53 mutation with sex, age, NF1 status, or tumor location,
suggesting a relatively minor role of this gene in MPNST
tumorigenesis [67]. We believe our results are in accordance with
the findings obtained from human patients, and consequently, our
mouse model may be more relevant to human MTT at the cellular
and molecular level. Therefore, studies are underway to gain a
better understanding of signaling molecules and pathways involved
in this rare and complex tumor.
Notably, the tumorigenesis observed here, though reproducible,
was not a mutually exclusive event. The mice that developed
Triton tumors simultaneously displayed complete sciatic nerve
regeneration and regeneration within the skeletal muscle.
Furthermore, this transformation could be abrogated when the
cells were differentiated beyond the ability to respond to local
signals or when their ability to receive the differentiation signal was
impaired. In this case, differentiating the cells toward the
neurogenic lineage prior to implantation abrogated tumorigenesis.
We believe that the ability to halt transformation by removing the
cells’ ability to respond to environmental cues (by differentiating
our cells prior to implantation) is important. Not only does this
finding substantiate the involvement of environmental signals in
the transformation of MDSPCs, it also provides us with ideas as to
how to avoid transformation. For example, by using a synthetic
‘‘nerve guide’’ [68], the MDSPCs may be protected from non-
neuronal environmental signals and ‘‘forced’’ to only undergo
neurogenic differentiation, while avoiding an oncogenic phenotype
later in the regeneration process.
In summary, our results demonstrate key findings that murine
muscle-derived stem/progenitor cells can functionally regenerate
peripheral nerve; however, these cells can undergo spontaneous
transformation at the site of nerve injury. Furthermore, this
transformation occurs in an environment and time-dependent
fashion and differentiating the cells prior to implantation
eliminates transformation. Our results also provide evidence that
experiments in tissue engineering and regenerative medicine
should be evaluated over a prolonged period of time, as the
transformation observed here occurs after 11 weeks post-implan-
tation, several weeks after complete histological regeneration. We
believe that in an effort to understand the origin of the perceived
niche-specific oncogenesis, using this unique mouse model, we
may reveal the biomarkers associated with human MTT and
potentially identify novel therapeutic strategies.
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